Project Grant R61NS138976
Award Date
9/19/24
Completion Date
8/31/26
Dollars Obligated
$1.5M
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63104, USA
Similar Awards
This federal Project Grant award of $1,587,553 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development and characterization of novel, central nervous system (CNS)-penetrant 5-HT3 receptor antagonists as potential treatments for neuropathic pain. The primary awardee, The Washington University in St. Louis, is collaborating with the University of Health Sciences and Pharmacy in St. Louis...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,494,049.00 in funding to The Washington University in St. Louis to conduct research focused on understanding how endogenous opioid systems regulate the analgesic properties of the central noradrenergic system. The research aims to determine how the loss of mu opioid...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $603,406 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Research Triangle Institute (RTI International) to develop GPR139 antagonists for enhancing the analgesic efficacy of opioid medications. The project aims to optimize the potency, selectivity, and drug-like properties of GPR139 antagonist compounds through medicinal chemistry and in vitro...
This $675,107 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) is supporting research conducted by Northeastern University to develop novel, non-opioid, and non-addictive analgesics for treating neuropathic pain. The primary objectives are to design and synthesize a series of new "dualsteric modulators" that act as both non-psychoactive...
This $650,079 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 aims to develop and optimize novel small-molecule probes targeting alpha9-containing nicotinic acetylcholine receptors (α9*-nAChRs) for the treatment of chronic inflammatory and neuropathic pain. Awarded to Northeastern University, the 5-year research project seeks to advance the understanding and therapeutic exploitation of α9*-nAChRs as a promising target for...
This $2,068,842 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to identify the role of prefrontal cortical dynorphin neuron activity and dynorphin release in modulating pain-induced negative affect and nociception. The research aims to use ex-vivo electrophysiology and in-vivo calcium imaging in mice to determine how pain influences the activity of...
This $838,750 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to investigate the role of the GCH1 gene and its encoded enzyme GTP cyclohydrolase 1 (GTPCH1) in chronic orofacial neuropathic pain. The award, provided to the University of Florida, will fund preclinical studies using an operant orofacial pain assay and chronic constriction injury model in rats...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,398,820.00 to fund research aimed at developing safer opioid analgesics and antagonists with the goal of reducing the adverse effects associated with traditional opioid medications. The key products and services to be delivered under this grant include: Synthesis and in vitro characterization of novel opioid receptor ligands that...
This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research into a novel, non-opioid spinal analgesic mechanism for the treatment of high-impact chronic pain. The $664,772 award to the University of Texas Southwestern Medical Center aims to dissect the signaling pathway involving the neurotensin receptor 2 (NTSR2)...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $290,312 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University in St. Louis. The grant, titled "PROMOTING EXCELLENCE THROUGH PAIN AND ADDICTION RESEARCH ENHANCEMENT (PREPARE) - ABSTRACT", will fund a postdoctoral training program to develop independent investigators capable of conducting clinical and translational research on the biopsychosocial mechanisms...